RAAS

Cloopen Receives NYSE Non-compliance Letter Regarding ADS Trading Price

Retrieved on: 
Wednesday, June 29, 2022
Securities Exchange Act of 1934, Company, Industry, Goal, Annual report, Terminology, Software as a service, New, Letter, RAAS, NYSE, Communication, Calendar, CC, SEC, Solution, Private Securities Litigation Reform Act, Government, Risk management

In the event that at the expiration of the six-month cure period, both a US$1.00 closing share price on the last trading day of the cure period and a US$1.00 average closing share price over the 30 trading-day period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures.

Key Points: 
  • In the event that at the expiration of the six-month cure period, both a US$1.00 closing share price on the last trading day of the cure period and a US$1.00 average closing share price over the 30 trading-day period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures.
  • Alternatively, the company can also demonstrate an accelerated cure based on a US$1.00 share price on both the last trading day of any calendar month within the six-month cure period and the average share price over the 30 trading days preceding the end of that month.
  • Cloopen aspires to drive the transformation of enterprise communications industry by offering innovative marketing and operational tactics and SaaS-based tools.
  • Further information regarding these and other risks, uncertainties or factors is included in Cloopen's filings with the SEC.

SS&C Blue Prism Honors WonderBotz with Regional Best Practices Partner of the Year and Regional Blue Prism Cloud Solution of the Year at Blue Prism World 2022

Retrieved on: 
Thursday, June 9, 2022
Linda, RPA, LinkedIn, SS, Software, Mentorship, Organization, Solution, Growth, Blue, SS&C, Technology, Robotics, RAAS, Adoption, Twitter, Blue Prism, Efficiency, Automation, Public relations, Management

PRINCETON, N.J., June 9, 2022 /PRNewswire/ -- WonderBotz, a global leader in the delivery of enterprise-grade automation and advanced AI solutions received two awards at SS&C Blue Prism's Partner Forum event 2022, recognizing their excellence in delivering SS&C Blue Prism's intelligent automation offering. These awards acknowledge key partners in SS&C Blue Prism's ecosystem while showcasing their expertise to digitally transform how organizations operate, compete, and innovate through delivery of intelligent automation.

Key Points: 
  • WonderBotz Co-CEO, Steve LaValle, shared: "We're thrilled to be recognized for not one, but two awards this year."
  • The recognition WonderBotz receives from Blue Prism year after year celebrates our strength in the marketplace, commitment to customer success, and mastery of the Blue Prism platform.
  • Our annual partner awards program showcases and celebrates our trusted and talented partners' incredible achievements.
  • We value our partner relationships and look forward to new opportunities as we transition to SS&C Blue Prism."

CinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease

Retrieved on: 
Wednesday, June 1, 2022
Kidney, Glomerular filtration rate, Primary aldosteronism, Adult, Achievement, Time, Stroke, Research, Degenerative disease, Safety, Annual report, American College, Security (finance), Inflammation, U.S. Securities and Exchange Commission, Diabetes, Blood, Hypertension, Biomarker, Chronic kidney disease, GFR, American College of Cardiology, GLOBE, Patient, Risk, RAAS, SBP, COVID-19, Death, Glomerulonephritis, Kidney disease, SEC, Population, American Heart Association, Cardiology, Blood pressure, CKD, Aldosterone, Disclosure, Pharmaceutical industry, Collection

WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) announced today that the first patient has been dosed in the Phase 2 figHTN-CKD trial evaluating baxdrostat (CIN-107), a highly selective aldosterone synthase inhibitor, in patients with uncontrolled hypertension and chronic kidney disease (CKD).

Key Points: 
  • WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor) announced today that the first patient has been dosed in the Phase 2 figHTN-CKD trial evaluating baxdrostat (CIN-107), a highly selective aldosterone synthase inhibitor, in patients with uncontrolled hypertension and chronic kidney disease (CKD).
  • Over 37 million people in the United States suffer from chronic kidney disease and progressive loss of kidney function.
  • Baxdrostat is a highly selective aldosterone synthase inhibitor that can significantly reduce aldosterone levels, offering the potential to not only improve uncontrolled blood pressure in CKD patients, but also ameliorate the negative impacts of aldosterone on kidney function.
  • The figHTN-CKD trial is a randomized, double-blind, placebo-controlled, multicenter, parallel-group, Phase 2 clinical trial designed to assess the safety and efficacy of baxdrostat (CIN-107) in patients with uncontrolled hypertension and CKD.

WonderBotz Partners with Krista Software for AI-led Intelligent Automation

Retrieved on: 
Thursday, May 26, 2022
Mentorship, AI, Robotics, Enterprise, Solution, Automation, Natural language processing, Efficiency, Industry, Partnership, RPA, Organization, Machine learning, LinkedIn, Twitter, RAAS, CEO, Medical device, Customer service, Krista, DALLAS

PRINCETON, N.J. and DALLAS, May 26, 2022 /PRNewswire/ -- WonderBotz, a global leader in the delivery of enterprise-grade automation and advanced AI solutions, announced today that it has partnered with Krista Software, the makers of "Krista". Krista is an intelligent automation platform that uses natural language and machine learning to personify legacy systems allowing people to "Ask Krista" for a business outcome. WonderBotz will embed Krista into its automation footprint to further differentiate its offerings and services.

Key Points: 
  • Krista is an intelligent automation platform that uses natural language and machine learning to personify legacy systems allowing people to "Ask Krista" for a business outcome.WonderBotz will embed Krista into its automation footprint to further differentiate its offerings and services.
  • "We strive to bring cutting-edge automation capabilities to our customers," said Steve LaValle, Co-CEO of WonderBotz.
  • John Michelsen, CEO and Founder at Krista Software added, "WonderBotz provides innovative and next generation automation capabilities to their customers, which makes this partnership very strategic for us.
  • For more information, visit wonderbotz.com and follow us on Twitter @WonderBotz and LinkedIn at linkedin.com/company/wonderbotz
    Krista Software develops the AI-led intelligent automation platform, Krista.

Cloopen Receives Notification from NYSE Regarding Delayed Filing of 2021 Annual Report

Retrieved on: 
Friday, May 20, 2022
Company, U.S. Securities and Exchange Commission, Annual report, New, Goal, Mission statement, File, Government, Solution, Form 6-K, NYSE Listed Company Manual, Securities Exchange Act of 1934, Industry, Form 20-F, Compliance, Communication, Terminology, Private Securities Litigation Reform Act, Software as a service, SEC, CC, RAAS, NYSE, Letter, Risk management

The anticipated filing date of the 2021 Annual Report is currently unknown, and the Company will file the 2021 Annual Report as soon as practicable.

Key Points: 
  • The anticipated filing date of the 2021 Annual Report is currently unknown, and the Company will file the 2021 Annual Report as soon as practicable.
  • The NYSE will closely monitor the status of the Company's late filing and related public disclosures for up to a six-month period from the due date of the 2021 Annual Report.
  • If the NYSE determines that an additional six-month trading period is not appropriate, suspension and delisting procedures will commence.
  • Cloopen aspires to drive the transformation of enterprise communications industry by offering innovative marketing and operational tactics and SaaS-based tools.

Cloopen Announces Changes in Independent Directors

Retrieved on: 
Wednesday, May 18, 2022
Business, MBA, Economics, Company, Private law, U.S. Securities and Exchange Commission, Language, Annual report, Nasdaq, LL.B, Beijing International Studies University, Goal, Literature, Government, Solution, University of Illinois Urbana-Champaign, Morrison & Foerster, New York University School of Law, Country Style Cooking, Tsinghua University, Securities Exchange Act of 1934, Industry, ELong, Ninetowns Internet Technology Group, Sichuan International Studies University, Board, Communication, Terminology, University, Private Securities Litigation Reform Act, Software as a service, PapayaMobile, CC, RAAS, Mori Hamada & Matsumoto, NYSE, Letter, Accenture, University School, Sustainability Accounting Standards Board, Management

BEIJING, May 18, 2022 /PRNewswire/ -- Cloopen Group Holding Limited (NYSE: RAAS) ("Cloopen" or the "Company") today announced changes in independent directors of the Company.

Key Points: 
  • BEIJING, May 18, 2022 /PRNewswire/ -- Cloopen Group Holding Limited (NYSE: RAAS) ("Cloopen" or the "Company") today announced changes in independent directors of the Company.
  • Mr. Adam J. Zhao agreed to be and was appointed as a new independent director to serve on the Board, effective May 18, 2022.
  • Mr. Tim Yimin Liu agreed to be and was appointed as a successor independent director to serve on the Board, effective May 18, 2022.
  • Mr. Adam J. Zhao served as the chief financial officer and board secretary of PapayaMobile from January 2015 to February 2021.

Cloopen Announced Formation of Independent Special Committee for Internal Investigation

Retrieved on: 
Tuesday, May 3, 2022
Board, Board of directors, Communication, Mission statement, Company, NYSE, Securities Exchange Act of 1934, RAAS, Securities Act of 1933, Disclosure, Independent Investigations Office, Sustainability Accounting Standards Board, Review, Industry, Independent, United States Congressional Joint Special Committee on Conditions of Indian Tribes, Phrase, KPMG, CC, Public Company Accounting Oversight Board, SEC, Software as a service, Solution, Committee, Audit

BEIJING, May 3, 2022 /PRNewswire/ -- Cloopen Group Holding Limited (NYSE: RAAS) ("Cloopen" or the "Company") today announced that it has formed an independent special committee to investigate certain employee misconduct and transaction irregularities.

Key Points: 
  • BEIJING, May 3, 2022 /PRNewswire/ -- Cloopen Group Holding Limited (NYSE: RAAS) ("Cloopen" or the "Company") today announced that it has formed an independent special committee to investigate certain employee misconduct and transaction irregularities.
  • The Company's Board of Directors (the "Board") has formed an independent special committee (the "Special Committee") to oversee an internal investigation of the issues that were raised to the Board's attention by KPMG Huazhen LLP ("KPMG") as discussed below (the "Independent Investigation").
  • The Special Committee has been empowered to retain independent advisors, including independent legal advisors and forensic accountants, in connection with the Independent Investigation.
  • These figures have not been independently verified by the Special Committee or its advisors and are subject to change as the Independent Investigation proceeds.

Cash Back Rewards Leader Ibotta Unveils B2B Solutions for Advertisers, Retailers, and Publishers

Retrieved on: 
Wednesday, April 6, 2022
Roman festivals, Population, USD, ROI, Sale, Consumer, Advertising, CPG, Apple, Program, Privacy, CEO, Data analysis, B2B, IPN, Walmart, The Denver Post, Industry, Digital, Technology, RAAS, Ecosystem, GLOBE, Solution, Awareness, Social media, Cryptocurrency, Online shopping, Sales, Ibotta, Google

That belief paid off with more than 40 million Ibotta app downloads to date and more than $1.1 billion (USD) in cash back reward offers redeemed.

Key Points: 
  • That belief paid off with more than 40 million Ibotta app downloads to date and more than $1.1 billion (USD) in cash back reward offers redeemed.
  • Unlike success metrics like gross impressions and click-through, each Ibotta offer is tied to the completed sale of an advertised product or service.
  • With the launch of the new IPN, Ibotta expands its scope to deliver B2B Rewards as a Service (RAAS) solutions to retailers, publishers, and advertisers in the CPG space and beyond.
  • Since the day we launched, Ibotta has looked to strengthen the connections between advertisers, retailers, and consumers, said Bryan Leach, founder and CEO of Ibotta.

FILING DEADLINE TODAY: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cloopen Group Holding Limited - RAAS

Retrieved on: 
Tuesday, February 8, 2022
GLOBE, News, Pomerantz, Company, LLP, IPO, Solution, RAAS, Decision-making, Annual report, American depositary receipt, NYSE, ADS, Lithium

NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cloopen Group Holding Limited (Cloopen or the Company) (NYSE: RAAS).

Key Points: 
  • NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cloopen Group Holding Limited (Cloopen or the Company) (NYSE: RAAS).
  • The investigation concerns whether Cloopen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Then, on March 26, 2021, just over six weeks after its IPO, Cloopen published its 4Q 2020 and FY 2020 financial results.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Revance, Paysafe, Organogenesis, and Cloopen Group and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, February 8, 2022
NASDAQ, GLOBE, News, Shareholder, E-commerce, III, Medicare, IPO, Solution, Company, RAAS, Decision-making, Organogenesis, Digital wallet, Therapy, Human, Federation, FOIA, Exercise, FDA, Registration statement, Review, Adult, Freedom of Information Act 2000, BLA, NYSE, ADS, Freedom, FTAC, Endpoint security, Paysafe, Defendant, Register, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Gambling, Lists of schools in England, Torticollis, Pharmaceutical industry, Medical device, Risk management, Cryptocurrency, Animal, Audit, Property management, P.C

Significantly, the Form 483 only came to light as a result of a Freedom of Information Act (FOIA) request directed to the FDA.

Key Points: 
  • Significantly, the Form 483 only came to light as a result of a Freedom of Information Act (FOIA) request directed to the FDA.
  • The lawsuit alleges throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • For more information on the Cloopen Group class action go to: https://bespc.com/cases/RAAS
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.